JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 138 filers reported holding JUNO THERAPEUTICS INC in Q3 2015. The put-call ratio across all filers is 2.12 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $41,859,000 | +1.9% | 915,750 | 0.0% | 0.26% | +7.5% |
| Q3 2017 | $41,081,000 | +50.1% | 915,750 | 0.0% | 0.24% | +35.8% |
| Q2 2017 | $27,372,000 | +34.7% | 915,750 | 0.0% | 0.18% | +15.8% |
| Q1 2017 | $20,320,000 | +17.7% | 915,750 | 0.0% | 0.15% | +10.1% |
| Q4 2016 | $17,262,000 | -37.2% | 915,750 | 0.0% | 0.14% | -38.1% |
| Q3 2016 | $27,482,000 | -21.9% | 915,750 | 0.0% | 0.22% | -18.9% |
| Q2 2016 | $35,201,000 | +0.9% | 915,750 | 0.0% | 0.28% | 0.0% |
| Q1 2016 | $34,881,000 | -13.4% | 915,750 | 0.0% | 0.28% | -10.1% |
| Q4 2015 | $40,266,000 | +8.1% | 915,750 | 0.0% | 0.31% | -13.6% |
| Q3 2015 | $37,262,000 | -23.7% | 915,750 | 0.0% | 0.35% | +16.1% |
| Q2 2015 | $48,837,000 | -12.1% | 915,750 | 0.0% | 0.30% | -26.7% |
| Q1 2015 | $55,549,000 | +16.2% | 915,750 | 0.0% | 0.42% | -16.3% |
| Q4 2014 | $47,820,000 | – | 915,750 | – | 0.50% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 25,948,799 | $1,132,937,000 | 100.00% |
| Biomark Capital Management Co. LLC | 1,602,562 | $70,465,000 | 85.76% |
| Omega Fund Management, LLC | 1,229,512 | $54,062,000 | 30.09% |
| Clarius Group, LLC | 218,942 | $9,626,000 | 2.93% |
| BB BIOTECH AG | 1,305,000 | $57,381,000 | 1.62% |
| Casdin Capital, LLC | 17,500 | $769,000 | 0.68% |
| Rock Springs Capital Management LP | 197,001 | $8,662,000 | 0.66% |
| BENNETT LAWRENCE MANAGEMENT L L C/NY | 38,850 | $1,708,000 | 0.55% |
| ArrowMark Colorado Holdings LLC | 383,749 | $16,873,000 | 0.46% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 68,848 | $3,027,000 | 0.38% |